Masimo's patents are used as the basis for innovation
1,322% more than the industry average
Irvine, California June 28, 2006 - Masimo Corporation, the inventor
of Pulse CO-Oximetry™ and Read-Through Motion and Low Perfusion pulse
oximetry ranked 7th overall in the Medical Device Industry in ipIQ's
2006 Patent Scorecard™. The Patent Scorecard is an
industry-by-industry ranking of corporate innovation and combines a
series of indicators to arrive at patent quality, technological
strength and breadth of impact. It has historically been
published in MIT's Technology Review and tracks the patent portfolios
of more than 2,500 of the world's top technology firms.
ipIQ's Current-Impact Index™, or CII, showcases the broader
significance of a company's patents by examining how impactful its
patents are across the industry and in specific product categories in
the most recent product cycles by measuring how frequently a company's
patents are referenced as prior inventions by other patents. A
CII of 100 represents average frequency. Masimo's CII was
calculated to be 1,422, which means that Masimo's patents are
referenced 1,322% more often than average. Masimo's CII score was
more than 10 times the average for the medical device sector.
"Masimo's performance is stellar both within the medical device
space and compared across every sector," stated Eric Gillespie,
Executive Vice President and COO of ipIQ. "The Current-Impact
Index is a quality measure designed to illustrate the strength of a
company's technology portfolio. Masimo's Current-Impact Index was
the highest score of the 2,500 plus companies included in the Patent
Scorecard."
Joe E. Kiani, CEO and Chairman of Masimo stated, "Masimo was founded
on the basis that to improve patient care and reduce cost of care,
breakthroughs were necessary in the area of noninvasive vital signs
monitoring. All of our peers were focusing on engineering longer
battery life and smaller foot print conventional monitors, and while
that is a worthy effort, we believed it should not be put in front of
the real task of making accurate and reliable noninvasive vital signs
monitors, which required inventions. We set out to solve a
problem that the industry thought was unsolvable and our innovations
have changed clinicians' expectations of noninvasive monitors and
dramatically improved patient care and reduced cost of care."
Mike Petterson, Vice President of Clinical Research of Masimo
stated, "Our first product line, Masimo Signal Extraction Technology
(SET)® pulse oximetry was the first pulse oximetry FDA cleared for
accuracy during patient motion and low perfusion and has ushered in a
new performance standard for this critical vital sign. Last year,
we introduced the second revolution in noninvasive vital signs
monitoring, which we call Rainbow™. Like pulse oximetry,
Rainbow is a spectroscopy based platform, but instead of using only two
wavelengths of light, our Rainbow platform utilizes multiple
wavelengths simultaneously. So far, we have two Rainbow
measurements, the noninvasive and continuous measurements of
carboxyhemoglobin and methemoglobin. We are working on additional
noninvasive, continuous measurements and hope to announce others over
the next few years."
About Masimo
Masimo develops innovative
monitoring technologies that significantly improve patient care-
helping solve "unsolvable" problems. In 1995, the company debuted
Read-Through Motion and Low Perfusion pulse oximetry, known as SET, and
with it virtually eliminated false alarms and increased pulse
oximetry's ability to detect life-threatening events. Over 70
independent clinical studies have confirmed that Masimo SET technology
allows clinicians to accurately monitor blood oxygen saturation in
critical care situations. In 2005 Masimo introduced Rainbow SET
and with it, Pulse CO-Oximetry, which, for the first time,
noninvasively monitors the level of carbon monoxide and methemoglobin
in the blood, allowing early detection and treatment of potentially
life-threatening conditions.
Masimo, founded in 1989, has the mission of "Improving Patient
Outcome and Reducing Cost of Care by Taking Noninvasive Monitoring to
New Sites and Applications." Additional information about Masimo and
its products may be found at www.masimo.com
Masimo, SET, Signal Extraction Technology and
Improving and Reducing Cost of Care by Taking Noninvasive Monitoring to
New Sites and Applications are registered trademarks of Masimo Corp.
Rainbow and Pulse CO-Oximetry are trademarks of Masimo Labs.
About ipIQ
ipIQ - Intellectual Property.
Intelligence Quotient. - is the world's leading Intellectual
Property advisor to investment banks, technology-driven companies, and
governments. With over three decades of experience, ipIQ utilizes
proprietary data, tools, analytics, and technology to leverage
patent-based Intellectual Property as an asset class. The Patent
Scorecard is published annually.
For additional information on the Patent Scorecared™ and ipIQ, go to www.ipIQ.com.
ipIQ™, Science Linkage™, Current-Impact Index™, and Patent Scorecard™
are trademarks of ipIQ - Intellectual Property, Intelligence Quotient
and are used with permission.
Contact:
Brad Langdale
949-297-7009
blangdale@masimo.com
Contact:
Jude Reter
312-205-7037
jreter@ipIQ.com